series-b
Stage
1
Investors
About
LabGenius Therapeutics develops therapeutic antibodies using an automated, machine-learning-driven discovery platform called EVA to identify and co‑optimize complex antibody molecules across multiple properties. The company is focused on creating selectivity‑enhanced antibodies, including multispecific formats, for the treatment of solid tumours.
Explore LabGenius Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.